eSense-Lab (ASX:ESE) is a biotech company seeking innovative and evidence-based applications of terpenes in the medical, wellness, cosmetics and nutritional markets.
The company has a unique technology to analyse and reverse engineer the exact terpene profiles of cannabis strains, without psychoactive ingredients and with lower production costs, by using alternate plant sources.
This technology also enables the creation of unique terpene profiles of rare and high-value plants, providing sustainability and lower production costs.
In addition to its existing products, the leadership team has established an optimised business model and developed broader research and development plans which include agreements for the development and distribution of products through joint venture partners.
ESE’s JV partners comprise Israeli company SeaLaria for the development of gelatinised Gracilaria red algae, Wise Wine, BetterAir and ANC – an Australian based manufacturer and wholesaler of cosmeceutical products.
Renewed leadership team
The company recently established a renewed leadership team to ensure that it is well-positioned to deliver on its strategic and operational goals into the future.
New appointments include Yoav Elishoov as chief executive officer and Moshe Hukaylo as chief financial officer.
Elishoov has brought a vast experience in commercial, market access, regulatory affairs and marketing roles with global pharmaceutical companies.
The company believes his multidisciplinary experience through various positions make him an ideal fit for the organisation.
Loan note agreements
On December 29, the company entered into loan note agreements with several sophisticated and professional investors to raise $812,000 to meet operational expenditure and fund working capital requirements.
The loan notes are unsecured and carry an interest rate of 12% per annum, which is payable in cash on the repayment date.
Terpenes have long been used in the treatment and management of common respiratory conditions.
They are naturally occurring compounds which account for the flavour and fragrance of plants, with each plant having its own unique terpene profile.
For example, a key ingredient of Vicks® VapoRub™ is menthol, a terpene found in mint.
The anti-viral activity of terpenes can range between a dose of 0.0006% and up to 0.01%, which is considered ‘very potent’.
eSense continues to research and test its proprietary terpene mix, TRP - ENV™, to confirm effectiveness against SARS virus (including the coronavirus related to COVID-19) with research to date yielding promising results.
Intends to develop superior sanitiser product
The company has been researching and testing its gel-based, alcohol-free sanitiser to evaluate terpene’s anti-viral synergistic effects.
ESE’s intention has been to develop a superior sanitiser product with a pleasant smell and feel, that provides added protection against bacteria and viruses, with a reduced ethanol content, making it safer and easier on the human skin.
Test results to date show that the Company has successfully developed a unique terpene profile (TRP-ENV) that can neutralise COVID-19 within 30 minutes.
The company also intends to focus on terpene infused CBD products of the highest grade, to provide oils, tinctures, creams and other products catering to consumers’ demands.
eSense has been conducting research into innovative, evidence-based applications of terpenes in medical areas such as Inflammation, virology, fibrosis, cancer neurodegeneration, and other diseases, as well as for the wellness, cosmetics and nutritional markets.